XML 77 R66.htm IDEA: XBRL DOCUMENT v3.24.3
Note 12 - Segment Data - Operating Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue from Contract with Customer, Excluding Assessed Tax [1] $ 57,833 $ 53,165 $ 116,003 $ 103,810
Gross profit 35,455 32,109 72,704 63,292
Operating expense 31,947 32,169 63,616 64,016
Operating income (loss) 3,508 (60) 9,088 (724)
Nonoperating expense, net 304 (1,265) (1,371) (1,538)
Operating Segments [Member]        
Gross profit 35,455 32,119 72,704 63,302
Operating expense 31,947 32,169 63,616 64,016
Operating income (loss) 3,508 (60) 9,088 (724)
Nonoperating expense, net (304) 1,265 1,371 1,538
Earnings (loss) before income taxes 3,812 (1,325) 7,717 (2,262)
Operating Segments [Member] | Sterilization and Disinfection Control [Member]        
Revenue from Contract with Customer, Excluding Assessed Tax [1],[2] 22,205 [3] 17,080 45,162 [4] 33,007
Gross profit [2] 15,172 12,476 30,730 24,067
Operating Segments [Member] | Clinical Genomics [Member]        
Revenue from Contract with Customer, Excluding Assessed Tax [1] 11,499 15,549 22,903 28,918
Gross profit 5,906 7,727 12,396 14,455
Operating Segments [Member] | Biopharmaceutical Development [Member]        
Revenue from Contract with Customer, Excluding Assessed Tax [1] 11,867 9,207 23,875 19,096
Gross profit 7,167 5,509 15,126 11,942
Operating Segments [Member] | Calibration Solutions [Member]        
Revenue from Contract with Customer, Excluding Assessed Tax [1] 12,262 11,329 24,063 22,789
Gross profit 7,210 6,407 14,452 12,838
Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]        
Gross profit [5] $ 0 $ (10) $ 0 $ (10)
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Includes post-acquisition GKE results during the three and six months ended September 30, 2024.
[3] Revenues of $5,863 from GKE are included in the Sterilization and Disinfection Control division during the three months ended September 30, 2024.
[4] Revenues of $12,117 from GKE are included in the Sterilization and Disinfection Control division during the six months ended September 30, 2024.
[5] Unallocated corporate expenses are reported within corporate and other.